文献速递乳腺癌放疗

全乳放疗常规分割与大分割患者报告结局及美容效果的五年纵向随机试验分析

Five-Year Longitudinal Analysis of Patient-Reported Outcomes and Cosmesis in a Randomized Trial of Conventionally Fractionated Versus Hypofractionated Whole-Breast Irradiation.
PubMed 文献 · Int J Radiat Oncol Biol Phys · 2021-05-13

该随机试验纳入287例接受肿块切除且切缘阴性的Tis-T2 N0-N1a M0乳腺癌女性,比较常规分割全乳放疗(50 Gy/25次加补量)与大分割全乳放疗(42.56 Gy/16次加补量)。五年随访显示两组患者报告结局与医生评估美容效果无显著差异,大乳房尺寸与肥胖同多个不良结局相关,支持大分割加补量的广泛采用。

要点

  • 五年内两组患者报告结局与医生评估美容效果无显著差异。
  • 无任何亚组在常规分割中獲得更好的患者报告结局或美容效果。
  • 罩杯≥D与更差的BCTOS美容、疼痛、FACT-B及体像评分相关。

核心结论

  • 常规分割与大分割全乳放疗加补量在五年随访中患者报告结局与医生评估美容效果相似。
  • 无相关亚组显示常规分割更优,支持大分割加补量的广泛采用。

研究设计与样本

  • 2011至2014年随机试验,纳入287例年龄≥40岁、Tis-T2 N0-N1a M0、肿块切除且切缘阴性的乳腺癌女性。
  • 随机接受常规分割全乳放疗50 Gy/25次加补量或大分割全乳放疗42.56 Gy/16次加补量。
  • 基线、6个月及此后每年至5年收集患者报告结局与医生评估美容效果。

主要发现

  • 共完成14,801次患者报告结局评估,中位年龄60岁,37%罩杯≥D,44%肥胖,30%接受化疗。
  • 五年内两组患者报告结局与美容效果无显著差异。
  • 罩杯≥D与更差BCTOS美容(P < .001)、BCTOS疼痛(P = .001)、FACT-B试验结局指数(P = .03)、FACT-B情绪健康(P = .03)及体像量表(P = .003)相关。
  • 超重者医生评估美容效果更差(P = .02),肥胖者更差(P < .001)。

关键数值与推荐

  • 常规分割全乳放疗方案为50 Gy/25次加补量。
  • 大分割全乳放疗方案为42.56 Gy/16次加补量。
  • 罩杯≥D与更差BCTOS美容评分相关(P < .001)。
  • 肥胖与更差医生评估美容效果相关(P < .001)。

临床怎么用

  • 大分割全乳放疗加补量可在包括接受化疗及肥胖高发人群中广泛采用。
  • 对大乳房尺寸和肥胖患者应关注多域不良结局风险,可考虑生活方式干预或替代放疗方案。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: There are limited prospective data on predictors of patient-reported outcomes (PROs) after whole-breast irradiation (WBI) plus a boost. We sought to characterize longitudinal PROs and cosmesis in a randomized trial comparing conventionally fractionated (CF) versus hypofractionated (HF) WBI. METHODS AND MATERIALS: From 2011 to 2014, women aged ≥40 years with Tis-T2 N0-N1a M0 breast cancer who underwent a lumpectomy with negative margins were randomized to CF-WBI (50 Gray [Gy]/25 fractions plus boost) versus HF-WBI (42.56 Gy/16 fractions plus boost). At baseline (pre-radiation), at 6 months, and yearly thereafter through 5 years, PROs included the Breast Cancer Treatment Outcome Scale (BCTOS), Functional Assessment of Cancer Therapy-Breast (FACT-B), and Body Image Scale; cosmesis was reported by the treating physician using Radiation Therapy Oncology Group cosmesis values. Multivariable mixed-effects growth curve models evaluated associations of the treatment arm and patient factors with outcomes and tested for relevant interactions with the treatment arm. RESULTS: A total of 287 patients were randomized, completing a total of 14,801 PRO assessments. The median age was 60 years, 37% of patients had a bra cup size ≥D, 44% were obese, and 30% received chemotherapy. Through 5 years, there were no significant differences in PROs or cosmesis by treatment arm. A bra cup size ≥D was associated with worse BCTOS cosmesis (P < .001), BCTOS pain (P = .001), FACT-B Trial Outcome Index (P = .03), FACT-B Emotional Well-being (P = .03), and Body Image Scale (P = .003) scores. Physician-rated cosmesis was worse in patients who were overweight (P = .02) or obese (P < .001). No patient subsets experienced better PROs or cosmesis with CF-WBI. CONCLUSIONS: Both CF-WBI and HF-WBI confer similar longitudinal PROs and physician-rated cosmesis through 5 years of follow-up, with no relevant subsets that fared better with CF-WBI. This evidence supports broad adoption of hypofractionation with boost, including in patients receiving chemotherapy and in a population with a high prevalence of obesity. The associations of large breast size and obesity with adverse outcomes across multiple domains highlight the opportunity to engage at-risk patients in lifestyle intervention strategies, as well as to consider alternative radiation treatment regimens.

来源:Int J Radiat Oncol Biol Phys,查看原文。版权归原作者所有。

引用

  1. Weng JK, Lei X, Schlembach P, et al. Five-Year Longitudinal Analysis of Patient-Reported Outcomes and Cosmesis in a Randomized Trial of Conventionally Fractionated Versus Hypofractionated Whole-Breast Irradiation. Int J Radiat Oncol Biol Phys. 2021. PMID: 33992718. doi:10.1016/j.ijrobp.2021.05.004

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。